Main Article Content
Urinary tract infections occupy a leading place among nephrological pathology and infectious diseases in general. The article deals with the aetiology and key stages of the pathogenesis of urinary system lesions. The main part of the paper contents the analysis of the efficacy, safety and expediency of using fluoroquinolones, particularly ciprofloxacin.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Stamm WE. Scientific and clinical challenges in the management of urinary tract infections. Am J Med 113 (1A): 1S–4S. PMID: 12113865
M. Grabe et al. Guidelines on Urologiсal Infections. European Association of Urology, 2015
Dombrovsky Y, Ivanov DD. Nifuratel usage in urinary tract infections treatment. KIDNEYS. 2014;4(10):21-24
Tan WC, Chlebicki MP. Urinary tract infections in adults. Singapore Med J. 2016 Sep; 57(9): 485–490. doi: 10.11622/smedj.2016153
Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in Antimicrobial Resistance among Urinary Tract Infection Isolates of Escherichia coli from Female Outpatients in the United States. Antimicrobial Agents and Chemotherapy. 2002;46(8):2540-2545. doi:10.1128/AAC.46.8.2540-2545.2002
Kahlmeter G Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. International Journal of Antimicrobial Agents. 2003;22(Suppl 2):49-52. doi: http://dx.doi.org/10.1016/S0924-8579(03)00229-2
Pickard R, Bartoletti R et al. Guidelines on Urologiсal Infections. European Association of Urology, 2016
Dombrovsky Y, Ivanova M. Modern approaches to complicate pyelonephritis treatment: cephalosporin usage and in particular ceftriaxone/sulbactam . Pochki. 2015;1(11):7-11.
Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Archives of Disease in Childhood. 2011;96(9):874-880. doi:10.1136/adc.2010.208843
Khorvash F, Mortazavi M, Hakamifard A, Ataei B. Comparison of the effect of co-trimoxazole and co-trimoxazole plus ciprofloxacin in urinary tract infection prophylaxis in kidney transplant patients. Advanced Biomedical Research. 2016;5:108. doi:10.4103/2277-9175.183669
Gluhovschi G, Gadalean F, Gluhovschi C, Velciov S, Petrica L, Bob F, Bozdog G, Kaycsa A. Is ciprofloxacin safe in patients with solitary kidney and upper urinary tract infection? Biomed Pharmacother. 2016;84:366-372. doi: 10.1016/j.biopha.2016.09.052
Karlowsky JA, Thornsberry C, Jones ME, Sahm DF. Susceptibility of Antimicrobial-Resistant Urinary Escherichia coli Isolates to Fluoroquinolones and Nitrofurantoin. Clin Infect Dis. 2003;36(2):183-187 doi:10.1086/345754
Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs Ciprofloxacin for Short-Course Treatment of Acute Uncomplicated Cystitis: A Randomized Trial. JAMA: the journal of the American Medical Association. 2012;307(6):583-589. doi:10.1001/jama.2012.80
Hanna-Wakim RH, Ghanem ST, El Helou MW, et al. Epidemiology and characteristics of urinary tract infections in children and adolescents. Frontiers in Cellular and Infection Microbiology. 2015;5:45. doi:10.3389/fcimb.2015.00045
Pyrig LA, Ivanov DD et al. Nefrologija: nacional'nyj pidruchnyk [Nephrology: national textbook] Donetsk: Zaslavsky O.Y.; 2014. 316p. (in Ukrainian)
Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A. European Emergence of Ciprofloxacin-Resistant Escherichia coli Clonal Groups O25:H4-ST 131 and O15:K52:H1 Causing Community-Acquired Uncomplicated Cystitis . Journal of Clinical Microbiology. 2008;46(8):2605-2612. doi:10.1128/JCM.00640-08
Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother. 2007 Aug;60(2):394-7J. doi: 10.1093/jac/dkm204
Gobernado M, Valdés L, Alós JI, Garcia-Rey C, Dal-Ré R, García-de-Lomas J et Spanish Surveillance Group for E. coli Urinary Pathogens. Quinolone resistance in female outpatient urinary tract isolates of Escherichia coli: age-related differences. Rev Esp Quimioter. 2007 Jun;20(2):206-10. PMID: 17893757
Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infections caused by multidrug-resistant Escherichia coli clonal group. N Engl J Med. 2001 Oct 4;345(14):1007-13. doi: 10.1056/NEJMoa011265
Haeseker M, Stolk L, Nieman F, Hoebe C, Neef C, Bruggeman C, Annelies V. The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. Br J Clin Pharmacol. 2013 Jan;75(1):180–185. doi:10.1111/j.1365-2125.2012.04337.x
Schmiemann G, Gágyor I, Hummers-Pradier E, Bleidorn J. Resistance profiles of urinary tract infections in general practice - an observational study. BMC Urology. 2012;12:33. doi:10.1186/1471-2490-12-33
Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B. et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU) EurUro. 2001;40(5):576–588. doi: 10.1159/000049840